烯二炔类抗肿瘤抗生素单克隆抗体导向药物研究进展  

Advances in Monoclonal Antibody Targeting Drugs of the Antitumor Antibiotics of Enediyne

作　　者：李丽[1] 顾觉奋[1] 吴梧桐[1] 

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京210009

出　　处：《药物生物技术》2005年第4期275-277,共3页Pharmaceutical Biotechnology

摘　　要：单克隆抗体对相应的抗原有高度特异性。因此,利用单抗作为特异性载体制成导向药物(免疫偶联物),对于治疗肿瘤有巨大潜力和引人瞩目的前景。文章对烯二炔类抗肿瘤抗生素.特别对新制癌菌素、力达霉素和calicheamicins及其单克隆抗体免疫偶联物的研究进展作了概述。Monoclonal antibody （McAb） was highly specific to its antigen. Therefore, it was very attractive to explore the possible use of McAb and its conjugate for cancer treatment. The antitumor antibiotics of enediyne including neocarzinostatin, lidamycin, calicheamicins and their monoclonal antibody immunoconjugate were specifically summarized.

关 键 词：单克隆抗体 烯二炔类 抗肿瘤抗生素 免疫偶联物 导向药物 

分 类 号：R979.1[医药卫生—药品]